Stage III NSCLC RWE in Chinese Patients

Trial Identifier: D4194R00009
Sponsor: AstraZeneca
NCTID:: NCT04023812
Start Date: July 2019
Primary Completion Date: February 2024
Study Completion Date: February 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, China Bei jing, China, China, 100044
China, China Bei jing, China, China, 100020
China, China Bei jing, China, China
China, China Chang Chun, China, China, 130021
China, China chengdu, China, China, 610042
China, China chengdu, China, China, 610041
China, China Da Tong, China, China, 030000
China, China Da Tong, China, China
China, China fen Yang, China, China
China, China guang zhou, China, China
China, China He Fei, China, China, 330006
China, China Hong Kong, China, China
China, China Ji nan, China, China, 2501117
China, China Nan Ning, China, China, 530021
China, China qing dao, China, China
China, China Shan Tou, China, China
China, China shanghai, China, China, 200030
China, China Shanghai, China, China, 200040
China, China Shanghai, China, China
China, China shijiazhuang, China, China, 050011
China, China shijiazhuang, China, China, 430079
China, China shijiazhuang, China, China, 063000
China, China tai zhou, China, China
China, China tian Jin, China, China
China, China Yin Chuan, China, China, 750004